AI
| Followers | 842 |
| Posts | 122795 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Wednesday, November 17, 2010 10:47:09 PM
NVS’ DEB025, a cyclophilin inhibitor for HCV, can potentially work
as monotherapy or in combination with other HCV drugs. DEB025
does not lead to rapid resistance when given as monotherapy because
it blocks a host protein rather than a viral protein. Below are 50-day
data for DEB025 dosed for 28 days as monotherapy or in combination
with Pegasys without ribavirin. Genotype-1/4 data are on the left and
genotype-2/3 data are on the right. (‘LQ’ = level of quantitation.)
Source: http://www.novartis.com/downloads/investors/presentations-events/pipeline-update/2010/2010-11-17-making-science_happen.pdf (slide #21)
as monotherapy or in combination with other HCV drugs. DEB025
does not lead to rapid resistance when given as monotherapy because
it blocks a host protein rather than a viral protein. Below are 50-day
data for DEB025 dosed for 28 days as monotherapy or in combination
with Pegasys without ribavirin. Genotype-1/4 data are on the left and
genotype-2/3 data are on the right. (‘LQ’ = level of quantitation.)
Source: http://www.novartis.com/downloads/investors/presentations-events/pipeline-update/2010/2010-11-17-making-science_happen.pdf (slide #21)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
